Salta al contenuto principale
Ricerc@Sapienza
Toggle navigation
Home
Login
Home
Persone
sabina.chiaretti@uniroma1.it
Sabina Chiaretti
Professore Associato
Struttura:
DIPARTIMENTO DI MEDICINA TRASLAZIONALE E DI PRECISIONE
E-mail:
sabina.chiaretti@uniroma1.it
Pagina istituzionale corsi di laurea
Curriculum Sapienza
Pubblicazioni
Titolo
Pubblicato in
Anno
Tyrosine kinase inhibitor discontinuation in non-allografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study
HAEMATOLOGICA
2025
Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel
BLOOD
2024
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL
JOURNAL OF CLINICAL ONCOLOGY
2024
Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel
BLOOD
2024
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study
HAEMATOLOGICA
2024
Ponatinib alone or with chemo-immunotherapy in heavily pre-treated Philadelphia-like acute lymphoblastic leukemia: a CAMPUS ALL real-life study
HAEMATOLOGICA
2024
CD146 MOLECULE EXPRESSION IN B CELLS ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALLs): A FLOW- CYTOMETRIC MARKER FOR AN ACCURATE DIAGNOSTIC WORK-UP
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
2024
Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia
BLOOD
2024
CD146 MOLECULE EXPRESSION IN B CELLS ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALLs): A FLOW- CYTOMETRIC MARKER FOR AN ACCURATE DIAGNOSTIC WORK-UP
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
2024
Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the GIMEMA ALL2820 Trial
BLOOD
2024
A five-gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia
HEMATOLOGICAL ONCOLOGY
2023
Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia
CANCERS
2023
DROPLET DIGITAL PCR DETECTION OF THE T315I BCR::ABL1 KD MUTATION IN ADULT PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
European Hematology Association (EHA) 2023 Open Library
2023
Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase
LEUKEMIA & LYMPHOMA
2023
Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
CANCERS
2023
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study
HAEMATOLOGICA
2023
Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
CANCERS
2023
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
BLOOD ADVANCES
2023
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study
BLOOD CANCER JOURNAL
2023
Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
CANCERS
2023
1
2
3
4
5
seguente ›
ultima »
Progetti di Ricerca
Dissecting and redefining the interplay between minimal residual disease and genetic features of Ph-like ALL:
The BCR/ABL1-like acute lymphoblastic leukemia (ALL) predictor: refinement of clinical and biological features of BCR/ABL1-like ALL patients, and validation and reproducibility of the diagnostic method
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma